PVM
ACTU

Palogic Value Management’s Actuate Therapeutics ACTU Stock Holding History

Palogic Value Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
+100,000
New +$414K 0.12% 154

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Palogic Value Management's ACTU Position: Q1 2026 in Review

Palogic Value Management opened a new position in Actuate Therapeutics (ACTU) in Q1 2026: 100,000 shares worth $274K. The stake represents 0.12% of the portfolio and ranks #154 among its holdings.

61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Palogic Value Management held 100,000 shares of Actuate Therapeutics worth $274K as of Q1 2026.
  • Actuate Therapeutics was a new Palogic Value Management position in Q1 2026.
  • Actuate Therapeutics made up 0.12% of Palogic Value Management's portfolio in Q1 2026, its #154 holding.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Palogic Value Management's 13F filing for Q1 2026, filed 15 May 2026.